A tumor responsive self healing prodrug hydrogel enables synergistic action of doxorubicin and miltefosine for focal combination chemotherapy. Issue 18 (16th April 2019)

• Record Type: Journal Article
• Authors: Balakrishnan, Biji; Joshi, Nitin; Thorat, Ketan; Kaur, Shahdeep; Chandan, Rajeet; Banerjee, Rinti
• Is Part Of: Journal of materials chemistry. Volume 7:Issue 18(2019)
• Page Start: 2920
• Page End: 2925
• Publication Date: 2019-04-16
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c9tb00454h
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Targeted therapy that facilitates the on-site, on-demand action of drug combinations is a promising approach for combination chemotherapy. Abstract : Targeted therapy that facilitates the on-site, on-demand action of drug combinations is a promising approach for combination chemotherapy. In situ gelling hydrogels were prepared using biopolymers with in-built imine and borate diol ester linkages to render pH and glucose responsiveness, respectively to achieve a triggered release of doxorubicin in tumor milieu. Doxorubicin prodrug hydrogel doped with miltefosine demonstrated a synergistic effect on inhibition of drug resistant MDA-MB 231 human breast cancer cells, suitable for focal combination chemotherapy.